Company intelligence / Profile preview

元羿生物科技

Shanghai, Shanghai, China

Ownership: Private
Development stage: Other

Overview

YuanYi Biotech is a clinical-stage biotechnology company based in Shanghai, China, specializing in the development of innovative gene therapies for ophthalmological and metabolic diseases. The company leverages its proprietary adeno-associated virus (AAV) vector platform to create long-lasting treatments that reduce the burden of frequent intraocular injections for patients with retinal disorders. Its lead candidate, YY001, is an AAV-based gene therapy designed to express anti-VEGF proteins for the treatment of neovascular age-related macular degeneration. YuanYi Biotech aims to address significant unmet medical needs by combining cutting-edge genetic engineering with efficient manufacturing processes.

Therapeutic areas: Ophthalmology
Modalities: Gene therapyBiologicAAV vectormRNA-based drugs
Industry: Biotech

Beyond the preview

Go deeper on 元羿生物科技.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 元羿生物科技.

Explore the full profile